Amphetamine vs Methylphenidate for ADHD Treatment

Primary Recommendation

The American Academy of Pediatrics recommends that both amphetamine and methylphenidate are equally effective first-line stimulant medications for ADHD, with large effect sizes for symptom reduction, but patients who fail to respond to one stimulant class should be switched to the other, as the combined response rate approaches 80-90% when both are tried sequentially 1, 2

Both medications demonstrate large effect sizes for reducing ADHD core symptoms (inattention, hyperactivity, impulsivity) in children and adolescents, with no clinically significant difference in overall efficacy between the two classes 1
Network meta-analysis data including over 10,000 children and adolescents confirms equivalent efficacy for both stimulant classes 1
Individual patients may respond preferentially to either amphetamine or methylphenidate, making sequential trials of both classes essential when the first agent fails 1

For preschool-aged children (4-5 years), methylphenidate is the recommended first-line stimulant due to stronger evidence in this age group, despite amphetamine having FDA approval for children under 6 years 3
In children with intellectual disability, methylphenidate shows lower effect sizes (0.39-0.52) compared to typically developing children (0.8-0.9), but remains first-line treatment 4, 5
For adults, amphetamine-based stimulants are preferred based on comparative efficacy studies 6

Decreased appetite, sleep disturbances, increased blood pressure and pulse, headaches, irritability, and stomach pain are the most common adverse effects for both medications 1
Both medications cause statistically significant but usually minor reductions in height and weight gain, which are dose-related and require monitoring 1
Regular monitoring of blood pressure and pulse is required for both stimulants, as small increases may be clinically relevant in patients with preexisting cardiovascular disease 1
Stimulant medications have not been shown to increase risk of sudden cardiac death after 2-3 years of treatment on average 3
Stimulants decrease rather than increase the risk of suicidal events in ADHD patients 1
Anxiety is not a contraindication to stimulant use, though careful monitoring is required 6

Start with either methylphenidate or amphetamine as first-line treatment (methylphenidate for preschoolers, amphetamine preferred for adults) 3, 2, 6
Long-acting formulations are strongly preferred over immediate-release due to better adherence, lower rebound effects, and consistent symptom control 6
If first stimulant fails, switch to the alternative stimulant class (amphetamine to methylphenidate or vice versa) before considering non-stimulants 2
If both stimulant classes are ineffective, contraindicated, or not tolerated, switch to atomoxetine, extended-release guanfacine, or extended-release clonidine 2
Only extended-release guanfacine and extended-release clonidine have FDA approval and evidence for adjunctive use with stimulants when monotherapy is insufficient 3

Do not prescribe stimulants for children whose symptoms do not meet DSM-5 criteria for ADHD 3
Do not assume lack of response to one stimulant class means failure of all stimulants; always trial the alternative class 1, 2
In preschool-aged children, only prescribe medication for moderate-to-severe dysfunction that has persisted ≥9 months and failed behavioral interventions 3
Do not abruptly discontinue guanfacine or clonidine due to risk of rebound hypertension; these must be tapered 3

The American Academy of Pediatrics recommends using immediate-release methylphenidate as an adjunct to methylphenidate extended-release for teenagers, due to its pharmacological consistency and ability to provide targeted symptom control during specific time periods 7
Using the same medication class for breakthrough coverage avoids introducing a new medication class with potentially different side effect profiles and tolerability issues 8

The American Academy of Pediatrics suggests starting with IR methylphenidate at approximately 30-50% of the total daily ER dose, administered in late afternoon to cover homework, driving, and evening activities 7
The AAP guidelines emphasize providing medication coverage for driving in adolescents with ADHD, noting that longer-acting or late-afternoon, short-acting medications might be helpful in this regard 7
The dose of IR methylphenidate should be titrated based on response, monitoring for rebound effects and sleep disturbances 8

Before prescribing any stimulant to an adolescent, it is essential to screen for substance abuse symptoms, as diversion and misuse are particular concerns in this age group 9, 7
If substance abuse is identified, assessment of substances must precede ADHD treatment 9, 7
Prescription refill requests should be monitored for signs of misuse or diversion, and formulations with lower abuse potential should be considered 7

Regular monitoring of blood pressure and pulse is necessary, as stimulants can cause small but potentially clinically relevant increases, especially with multiple daily doses 8
Tracking appetite, sleep, and growth parameters is also crucial, as these are the most common adverse effects requiring dose adjustment 8
Assessing for rebound irritability or symptom worsening as the ER formulation wears off before the IR dose is given is also important 8

Prescribing the short-acting dose too late in the day (after 5-6 PM) should be avoided, as it can interfere with sleep onset, which is already a common stimulant side effect 8